Breaking News, Collaborations & Alliances

BeiGene Earns Merck Serono Milestone

BGB-283 BRAF inhibitor achieves clinical milestone

Author Image

By: Kristin Brooks

Managing Editor, Contract Pharma

BeiGene, Co. has achieved a clinical milestone in its collaboration with Merck Serono for BGB-283, a second-generation BRAF inhibitor candidate in Phase I development, triggering a $5 million payment from Merck.   The companies entered the BGB-283, two-asset strategic collaboration in 2013. In December 2013, BeiGene began a Phase I trial of BGB-283 in patients with BRAF or KRAS mutations. The drug offers the potential to treat cancers that harbor BRAF mutations and/or aberrations in the RAS-MAPK...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters